ARCHIVES

Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa.

This article is from The Cancer Letter archive.

Vol. 31 No. 01 | January 7, 2005

Download PDF Visit The Full Archive

Related Articles

Gleevec For KIT-positive Tumors Shows 92 Percent Overall Survival

July 29, 2011

Study Finds Comparable Accuracy For Virtual And Standard Colonoscopy

September 26, 2008

Wendy Will Case Found Invites Applications For Small Grants

April 5, 1991

Adding Velcade Increased Overall Survival By 13.3 Months at Five-Year Analysis

December 30, 2011

Biopsies Could Be Reduced By Computer-Aided-Detection

December 26, 2003

“Too much [of NCI’s] planning is reactive rather than proactive. As a consequence, vision suffers.”

July 7, 1995